Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,085 across all filing types
Latest filing 2019-04-23 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
2018年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2018年度募集资金存放与使用情况的专项报告" which translates to a "Special Report on the Storage and Use of Raised Funds for the Year 2018." It details the amount of funds raised, their allocation, usage, and management according to regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document includes detailed tables on funds raised, usage, balances, and compliance with regulatory guidelines. It is a specialized report focusing on the management and use of capital raised by the company, not a general annual report or earnings release. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is substantive (7506 characters) and contains detailed financial data related to fundraising usage, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2019-04-23 Chinese
第二届董事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the company's second board meeting, including approval of the 2018 annual general manager work report, 2018 board work report, audited 2017 financial report, 2018 financial statements, 2018 annual report and its summary, profit distribution plan, and other related matters. It also mentions that these reports and documents are published on external websites for investor review and that these resolutions will be submitted to the 2018 annual shareholders meeting for approval. The document is not the annual report itself but a board meeting resolution announcement regarding the annual report and related financial documents. It contains detailed voting results and decisions but does not include the full financial statements or the full annual report text. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official regulatory announcement of board meeting resolutions related to the annual report and other corporate matters, not the annual report itself.
2019-04-23 Chinese
华西证券股份有限公司关于公司的定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "定期现场检查报告" which translates to "Periodic On-site Inspection Report" by a sponsoring securities company regarding a listed company. The content focuses on detailed compliance checks on corporate governance, internal controls, information disclosure, use of raised funds, and performance, with checklists and findings. It is a formal inspection report rather than an announcement or a summary. The document length is 3311 characters, which is relatively short, but the content is substantive and detailed, not merely an announcement of a report. The nature of the document aligns with an Audit Report / Information (AR) as it involves regulatory inspection results and compliance verification, not a full annual report or earnings release. It is not a certification or a simple announcement, so it does not fall under RNS or RPA. Therefore, the best classification is AR (Audit Report / Information). FY 2019
2019-04-23 Chinese
华西证券股份有限公司关于公司2018年度关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Huaxi Securities regarding related party transactions of Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. for the year 2018. It discusses compliance with regulatory requirements, internal management systems, specific related party transactions, and internal decision-making procedures. The document is a standalone audit or verification report focusing on related party transactions, not a full annual report or financial statement. It does not contain comprehensive financial data or management discussion but is an audit-related opinion on a specific aspect (related party transactions) for a fiscal year. Therefore, it fits best under Audit Report / Information (AR). The document length is 2027 characters, which is consistent with a detailed audit opinion rather than a brief announcement or a full annual report. FY 2018
2019-04-23 Chinese
2018年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2018年度监事会工作报告" which translates to "2018 Supervisory Board Work Report". It details the supervisory board's activities, evaluations, and opinions on the company's operations, financial status, internal controls, and compliance during the 2018 fiscal year. It includes summaries of meetings, oversight on financial reports, internal control evaluations, and other supervisory functions. The document is a comprehensive report on the supervisory board's work rather than a full annual report or audit report. It is not an announcement or a brief notice but a detailed report on supervisory activities. This type of document aligns best with the category of Management Reports (MDA), which covers management's detailed explanations of financial results, business trends, and outlook, including supervisory board reports. The document length (3728 characters) is sufficient for a substantive report but not a full annual report (10-K). Therefore, the classification is MDA with high confidence.
2019-04-23 Chinese
2018年度独立董事述职报告（郑斌）
Board/Management Information Classification · 95% confidence The document is titled as the "2018年度独立董事述职报告" which translates to "2018 Annual Independent Director's Work Report." It details the independent director's attendance at board meetings, shareholder meetings, committee meetings, and their independent opinions on various company matters during 2018. The content focuses on governance, oversight, and the independent director's role in supervising company operations and protecting shareholder interests. There is no presentation of financial statements or detailed financial performance data typical of annual or interim reports. Instead, it is a report on board/management activities and governance oversight by an independent director. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is substantial and contains detailed narrative and opinions, not just an announcement or certification, so it is not RNS or RPA. Hence, the classification is MANG with high confidence.
2019-04-23 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.